Safety of G-CSF in patients with COVID-19
10.12092/j.issn.1009-2501.2024.03.012
- Author:
Heng LIU
1
;
Zijian LI
2
Author Information
1. The First Clinical Medical College, Lanzhou University
2. Department of Hematology, The First Hospital of Lanzhou University
- Publication Type:Journal Article
- Keywords:
benefit;
COVID-19;
G-CSF;
risk;
SARS-CoV-2
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(3):334-338
- CountryChina
- Language:Chinese
-
Abstract:
COVID-19, a disease caused by SARSCoV-2 infection, has caused a global pandemic in a short time. The key immunopathological features of COVID-19 include lymphopenia, neutropenia, cytokine storm and related Immune damage to parenchymal organs such as lung. Granulocyte colony stimulating factor (G-CSF) can cause excessive inflammatory reaction, which may aggravate the condition of some patients. Therefore, it is controversial whether COVID-19 should be treated with G-CSF, and clinicians need to evaluate the effectiveness and safety of G-CSF according to the specific conditions of each patient.
